Cargando…
Prevention of Heart Failure in Hypertension—Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study
BACKGROUND: Hypertension is a known risk factor for heart failure (HF), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy (LVH). We studied the extent to which blood pressure (BP) change and evolving LVH contribute to the effect that lisinopril, doxazosin, and amlodip...
Autores principales: | Johnson, Kyle, Oparil, Suzanne, Davis, Barry R., Tereshchenko, Larisa G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507192/ https://www.ncbi.nlm.nih.gov/pubmed/30943832 http://dx.doi.org/10.1161/JAHA.119.011961 |
Ejemplares similares
-
Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT
por: Shahu, Andi, et al.
Publicado: (2019) -
Comments on ALLHAT and doxazosin
por: Krakoff, Lawrence R
Publicado: (2001) -
Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?
por: Gavras, Irene, et al.
Publicado: (2001) -
Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid-lowering component of ALLHAT
por: Rahman, Mahboob, et al.
Publicado: (2013) -
A new era in hypertension research: discussing the findings of ALLHAT
por: Furberg, Curt D
Publicado: (2001)